How is HER2-Positive Breast Cancer graded and what does the grade mean

HER2-Positive Breast Cancer: Understanding HER2 Grading

Great question! HER2 grading is a critical part of understanding your breast cancer and determining treatment options. Let me explain how this works.

How HER2 is Graded

HER2 (human epidermal growth factor receptor 2) is graded using a system called immunohistochemistry (IHC), which uses special stains to visualize the HER2 protein in your tumor tissue. The grading scale goes from 0 to 3+:

• 0 (Negative): No HER2 protein detected
• 1+ (Low): Minimal HER2 protein present
• 2+ (Intermediate): Moderate HER2 protein present
• 3+ (Positive): High levels of HER2 protein present

What the Grade Means

The grade tells your doctors how much HER2 protein is driving your cancer's growth. HER2 is a growth signal—think of it like an accelerator pedal for cancer cells. The more HER2 present, the more aggressively the cancer may grow, but importantly, the more it can be targeted with specific anti-HER2 drugs.

According to clinical guidance on proteomics and HER2 expression, patients with very high HER2 expression (measured at levels above 750 amol per microgram) who received anti-HER2 therapy showed excellent outcomes with no disease events at 6-7 years of follow-up. This demonstrates how powerful HER2-targeted treatment can be when HER2 levels are high.

Important Context: HER2 Expression Varies

Here's something important that's changing in the field: HER2 isn't simply "positive" or "negative"—it exists on a spectrum. Research shows that:

• Approximately 15-20% of breast cancers are IHC 3+ (clearly HER2-positive)
• The remaining 80% fall into the 0, 1+, and 2+ categories
• Even some IHC 0 and 1+ tumors can have detectable HER2 protein

This matters because newer drugs like trastuzumab deruxtecan (Enhertu) work effectively in patients with low HER2 expression (IHC 1+ and 2+), expanding treatment options beyond traditional HER2-positive patients.

What This Means for Your Treatment

Your HER2 grade directly influences which treatments your oncologist will recommend:

For HER2-Positive (3+) Breast Cancer:

• Dual anti-HER2 therapy is standard—combining two different anti-HER2 drugs (like trastuzumab and pertuzumab) often produces better outcomes than using one alone
• Antibody-drug conjugates (drugs that deliver chemotherapy directly to HER2-positive cells)
• Hormone therapy (if your cancer is also hormone receptor-positive)
• Chemotherapy combined with anti-HER2 drugs

Questions to Ask Your Oncologist

Since HER2 grading is so important for your treatment plan, here are specific questions to discuss:

1. What is my exact HER2 grade (0, 1+, 2+, or 3+), and what does this mean for my specific situation?
2. Are there any additional HER2 tests (like FISH or proteomics) that would provide more detailed information about my HER2 levels?
3. Which anti-HER2 drugs are you recommending, and why these specific ones for my case?
4. How will we monitor my response to anti-HER2 therapy?
5. If my cancer becomes resistant to one anti-HER2 drug, what are the backup options?

Key Takeaway

Your HER2 grade is one of the most important predictors of how your cancer will respond to treatment. The good news is that HER2-positive breast cancer is one of the most treatable types of cancer precisely because we have multiple effective drugs that target HER2. Your oncologist will use your HER2 grade along with other factors (hormone receptor status, stage, your overall health) to design a personalized treatment plan.

---

Sources:

• CancerPatientLab Webinars: "Clinical Guidance from Proteomics" (Sheeno Thyparambil) - discusses HER2 protein distribution, expression levels, and treatment outcomes
• CancerPatientLab Webinars: "Making Decisions in the Complexity of Healthcare" (Michael Liebman, PhD) - addresses HER2 grading nuances and the shift from binary positive/negative classification to spectrum-based understanding
• CancerPatientLab Webinars: "Bringing Novel Immune System Tests from Research to Clinical Use" (Keith Wharton) - explains HER2 testing history and the evolution of HER2-targeted therapies including Enhertu

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.